Lördag 21 December | 15:41:36 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-08-28 08:30 Kvartalsrapport 2025-Q2
2025-05-14 N/A Årsstämma
2025-05-13 08:30 Kvartalsrapport 2025-Q1
2025-02-14 10:30 Bokslutskommuniké 2024
2024-11-15 - Kvartalsrapport 2024-Q3
2024-11-05 - Split BIOVIT 10:1
2024-10-25 - Extra Bolagsstämma 2024
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning BIOVIT 0.00 SEK
2024-05-14 - Årsstämma
2024-05-13 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-11-24 - Extra Bolagsstämma 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-25 - Årsstämma
2023-05-17 - X-dag ordinarie utdelning BIOVIT 0.00 SEK
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-14 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-30 - Kvartalsrapport 2022-Q2
2022-06-20 - Årsstämma
2022-06-01 - Extra Bolagsstämma 2022
2022-05-30 - Kvartalsrapport 2022-Q1
2022-05-19 - X-dag ordinarie utdelning BIOVIT 0.00 SEK
2022-02-14 - Bokslutskommuniké 2021
2021-11-19 - Kvartalsrapport 2021-Q3
2021-08-31 - Kvartalsrapport 2021-Q2
2021-05-14 - X-dag ordinarie utdelning BIOVIT 0.00 SEK
2021-05-12 - Årsstämma
2021-05-07 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-12-15 - Extra Bolagsstämma 2020
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-31 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning BIOVIT 0.00 SEK
2020-05-14 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-15 - X-dag ordinarie utdelning BIOVIT 0.00 SEK
2019-05-14 - Årsstämma
2019-05-09 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-31 - Kvartalsrapport 2018-Q2
2018-05-15 - X-dag ordinarie utdelning BIOVIT 0.00 SEK
2018-05-14 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-02-26 - Bokslutskommuniké 2017
2017-10-30 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-30 - Årsstämma
2017-05-12 - Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Bio Vitos Pharma är verksamt inom medicinteknik. Bolaget utvecklar och kommersialiserar produkter för upptäckande av hemolys i blodprover. Bolaget har utvecklat produkter som säkerställer att hemolysen upptäcks i ett tidigt stadie, vilket medför att blodprovet kan tas om hand omedelbart. Bolaget utvecklar även digital avläsning som används som komplement till huvudprodukten. Bio Vitos Pharma grundades 2010 och har huvudkontor i Karlstad.
2024-02-12 13:50:00

KFUM Kalmar and Bio Vitos Pharma have signed a collaboration agreement to conduct a research study entitled "Effect of oral iron succinate on iron deposits and exercise capacity in female athletes." This agreement marks an important step forward in strengthening the scientific evidence and investigating Succifer's potential benefits for female athletes.

The study will include 60 female athletes from Kalmar and will be conducted under the direction of Linnaeus University. Participants will be divided into three groups of 20 participants in each group to compare the effects of Succifer treatment, placebo and no treatment (control group). Each participant will undergo physical tests and blood tests before, during and after the study and commit to follow a given dietary instruction and keep daily diet and exercise diaries during the study.

- We are very pleased to have entered into this collaboration agreement with Bio Vitos Pharma to participate in this important research study. We are convinced that the study will provide valuable insight into how Succifer can affect iron stores and training capacity in female athletes, and we look forward to contributing to the scientific research in this area, says Jonas Sjöberg, Director of Sports at KFUM Kalmar.

- This collaboration is an important milestone for us in our endeavor to expand the scientific basis and our understanding of Succifer's effects on athletes. We are grateful for both KFUM Kalmar's and Linnaeus University's commitment and look forward to working together to strengthen the scientific evidence and explore the potential of our product, says CEO Jesper Birgemo.

For further information, contact:

Bio Vitos Pharma AB (publ)

Jesper Birgemo, CEO

Tel: +46 (0) 70 895 39 34

About Bio Vitos Pharma AB

Bio Vitos Pharma develops, produces, and commercializes iron succinate for the treatment of iron deficiency within the parent company as well as a service for close-to-patient detection of hemolysis in blood samples within the framework of a wholly owned subsidiary, Hemcheck Management AB. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB is the Certified Adviser to the company.